Monopyridinium oximes

HI-6 is considered to be a very promising bispyridinium oxime in medical treatment following exposure to most nerve agents. A disadvantage of HI-6 compared to other available oximes is its lack of stabihty in aqueous solutions. Both HI-6 and obidoxime are apparently more effective against nerve agents than the monopyridinium oximes P2S or 2-PAM (Aas, 2003). 

Kuca, K., Picha, J., Cabal, J., Liska, F. (2004b). Synthesis of the three monopyridinium oximes and evaluation of their potency to reactivate acetylcholinesterase inhibited by nerve agents. J. Appl. Biomed. 2 51-6. 

Picha et al. (2005) returned to monopyridinium compounds (35) with a hydroxyiminomethyl group modified in the side-chain, with the aim of improving the nucleophilicity of this group (Figure 66.28). From the eight oximes prepared and tested, none achieved better reactivation potency if compared with pralidoxime, obidoxime, or HI-6 (Picha et al., 2005 Jun et al, 2008). 

---